As Q3 2025 comes to a close, HCPLive reviews notable advances in psychiatry, highlighting regulatory updates, emerging therapies, and key clinical trial findings. Clinicians have seen the FDA propose an acetaminophen label change, advance leucovorin approval for cerebral folate deficiency, grant Fast Track and Breakthrough Therapy designations for NRX-100 and TSND-201, and review lumateperone for schizophrenia relapse prevention. Phase 2 and 3 data from trials of MM120, ammoxetine, and RE104 offer promising options for generalized anxiety disorder, major depressive disorder, and postpartum depression, reflecting evolving treatment strategies.
